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Abstract. Caudal type homeobox 2 (CDX2) has been 
well-established as a diagnostic marker for colorectal cancer 
(CRC); however, less is known about its regulation, particu-
larly its potential interactions with the DNA repair proteins, 
adenomatous polyposis coli (APC) and β-catenin, in a 
non-transcriptional manner. In the present study, the protein 
expression of CDX2 was analyzed, depending on the expres-
sion of the DNA repair proteins, mismatch repair (MMR), 
O6-methylguanine DNA methyltransferase (MGMT) and 
excision repair cross-complementing 1 (ERCC1), and its impor-
tance in Wnt signaling was also determined. A total of 101 
liver metastases were punched into tissue microarray (TMA) 
blocks and serial sections were cut for immunohistochemistry. 
For each protein, an immunoreactive score was generated 
according to literature data and the scores were fitted to TMA. 
Subsequently, statistical analysis was performed to compare 
the levels of expression with each other and with clinical data. 
CDX2 loss of expression was observed in 38.5% of the CRC 
liver metastasis cases. A statistically significant association 
between CDX2 and each of the investigated MMRs was 
observed: MutL Homolog 1 (P<0.01), MutS protein Homolog 
(MSH) 2 (P<0.01), MSH6 (P<0.01), and postmeiotic segrega-
tion increased 2 (P=0.040). Furthermore, loss of MGMT and 
ERCC1 was also associated with CDX2 loss (P=0.039 and 
P<0.01, respectively). In addition, CDX2 and ERCC1 were 
inversely associated with metastatic tumor size (P=0.038 and 
P=0.027, respectively). Sustained CDX2 expression was asso-
ciated with a higher expression of cytoplasmic/membranous 
β-catenin and with nuclear APC expression (P=0.042 and 
P<0.01, respectively). In conclusion, CDX2 loss of expres-
sion was not a rare event in liver metastasis of CRC and the 
results suggested that CDX2 may be involved in mechanisms 
resulting in the loss of DNA repair protein expression, and in 
turn methylation; however, its exact function in this context 
remains to be elucidated.
Introduction
Colorectal cancer (CRC) is the third most deadly cancer 
worldwide accounting for more than 600,000 deaths annu-
ally (1). At the diagnosis, a quarter of the patients with primary 
CRC have synchronous hepatic metastasis, and more than 50% 
of the patients with CRC will develop liver metastases in the 
course. Almost half of the patients undergoing resection for 
primary CRC eventually develop metachronous liver metas-
tasis. Survival in metastatic cases is rarely longer than three 
years (2). Interestingly, although caudal type homeobox 2 
(CDX2) is widely used in the daily routine diagnostic, there are 
less than sixty publications in the last sixty years performed on 
human tissue investigating the role of CDX2 (3).
The Cdx family of transcription factors contributes also to 
the CRC phenotype, but a mechanism by which CDX2 expres-
sion is lost or downregulated in colorectal tumors is currently 
not clear. The CDX2 is necessary for the proper development of 
the intestinal tract and is crucial for development and homeo-
stasis of the intestinal epithelium throughout life (1). The role 
of Cdx2 in colorectal carcinogenesis is multi-sided. The CDX2 
expression is reduced in CRC and its expression is inversely 
correlated to tumor grade, tumor stage and lymph node metas-
tasis (4). Loss of CDX2 expression can strongly predict high 
level CpG island methylation phenotype (CIMP-H) indepen-
dently from microsatellite status of CRCs. Thus Cdx2 was 
proposed as a surrogate marker for CIMP-H (5). In addition, 
CDX2 was attributed to play a regulatory role in apoptosis and 
DNA repair. Colon epithelium with decreased CDX2 expres-
sion lead to impaired apoptosis potential after γ-irradiation, 
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thus resulting in higher resistance to genotoxic stress. Besides, 
the effect of CDX2 in DNA repair activity can contribute to its 
attributed tumor suppressor function (6).
DNA methylation of tumor suppressor genes resulting in 
its transcriptional inactivation and has been identified as an 
important mechanism. CIMP characterized by the extensive 
hypermethylation of multiple CpG islands, and belongs to one 
of the major mechanisms in the colorectal carcinogenesis (7). 
O6-methylguanine DNA methyltransferase (MGMT), a surro-
gate marker for CIMP, gene promoter methylation plays an 
important role in colorectal carcinogenesis. Loss of MGMT 
expression, which is secondary to gene promoter methyla-
tion, occurs in approximately 30-40% of metastatic CRC. In 
addition, loss of MGMT expression results in high response to 
alkylating agents (i.e., dacarbazine or temozolomide) (8). Thus, 
MGMT is believed to have predictive potential for therapy.
A further level of DNA damage defence mechanism is 
represented by the mismatch repair (MMR) system, which 
take part not only in the DNA repair processes, but also in 
the regulation of cell cycle check-points and apoptosis (9). 
Deficiency of MMR proteins (i.e., MLH1 and MSH2) is 
responsible for resistance to various chemotherapeutic drugs 
and subsequently for resistance to apoptosis (9). Interestingly, 
loss of MGMT expression is more frequent in CRC with micro-
satellite instability, suggesting that methylated MGMT selects 
cellular clones with MMR deficient status (8). Moreover, 
MMR deficiency is also correlated with loss of CDX2 (10).
Excision repair cross-complementing 1 (ERCC1) is a 
structure specific DNA repair endonuclease responsible for 
5' incision (5'-endonuclease), a key enzyme in nucleotide 
excision repair (NER) pathway and is essential for repair of 
platinum-DNA adducts, thus associated with therapy resistance 
to platinum-containing compounds (i.e., cisplatin) (11,12).
Aberrant β-catenin expression and disturbed Wnt signaling 
is recognized as an important event in the genesis of several 
malignancies, especially in CRC. β-catenin mutations or 
loss-of-function mutations of the adenomatous polyposis coli 
(APC) tumor suppressor gene appear to be crucial steps in 
the progression of this disease (13). APC and β-catenin were 
found to traffic independently from each other into and out of 
the nucleus in response to internal and external signals. This 
fact has prompted debate about the previously proposed role 
of APC as a β-catenin chaperone (14). Germline mutations in 
the APC gene cause familial adenomatous polyposis (FAP), 
and over 80% of CRCs (both inherited and sporadic) carry 
truncating mutations that inactivate the APC protein. Most of 
these mutations occur in the so-called ‘mutation cluster region’ 
of the APC gene, accounting for a truncated protein incapable 
of binding regulatory proteins (i.e., Axin) or associating with 
microtubules. The relevance of truncating mutations for 
β-catenin is enormous: Mutated APC cannot stimulate its 
degradation (because of its failure to bind Axin), although 
APC still can bind to β‑catenin (albeit less efficiently) (14,15). 
β-catenin has been observed to accumulate in the nuclei of 
colon cancer cells, which results from the inability of APC to 
promote β-catenin degradation, rather than a lack of export 
function, leading to nuclear accumulation of β-catenin in 
APC-mutant tumor cells (14). There are only few studies that 
focused on interactions between CDX2 and Wnt signalling 
in colon cancer. It has been demonstrated that CDX2 can 
inhibit the transcriptional activity of β-catenin/TCF lines in a 
non-transcriptional way (4).
Expression of CDX2 in association with DNA repair 
proteins and members of Wnt signaling pathway has not been 
studied previously in liver metastasis of CRC. In this study, 
we analysed the expression distribution of CDX2 in matters 
of expression status of DNA repair proteins (MMR proteins, 
MGMT and ERCC1), APC, and β-catenin. Furthermore, we 
correlated CDX2 protein expression with clinical data.
Materials and methods
Tissue samples. Formalin-fixed paraffin-embedded surgical 
specimens of liver metastasis of CRC were selected from the 
archives of the Institute of Pathology at the University Hospital 
of Heidelberg. Hundred and one patients without neo-adjuvant 
chemotherapy (64 male, 37 female; mean age 62 years) were 
included. Tumor size was between 5 mm and 16 cm in diam-
eter. 12 cases showed mucinous adenocarcinoma histology and 
89 cases showed histology of adenocarcinoma NOS. We had only 
two cases with grade 1 adenocarcinoma, 83 cases had grade 2 
and 12 cases grade 3 histology. Serial paraffin sections were cut 
at 4 µm for immunohistochemistry. Important clinical data, such 
as: Age, gender, size and number of metastases were collected 
from histological reports. Tissue samples were provided by the 
tissue bank of the National Centre for Tumor Diseases (NCT, 
Heidelberg, Germany) in accordance with the regulations of 
the tissue bank and the approval of the ethics committee of 
Heidelberg University according to ethical standards formulated 
in the Declaration of Helsinki 1975 (revised in 1983).
Tissue microarray (TMA). TMA blocks were punched from 
paraffin-embedded human liver specimens with a tissue 
microarrayer (Beecher Instruments, Sun Prairie, WI, USA). 
From each case, two cores of tumor tissue were punched with 
a diameter size of 1.6 mm and two muscle cores were used 
for orientation of the TMA slides. Therefore serial sections 
were cut from the TMA block. So far, there is no standardised 
operating protocol or universal agreement for sampling and 
staining of TMA blocks and slides. The general consensus is 
that at least two 0.6 mm cores adequately represent for immu-
nohistochemical changes (16,17).
Immunohistochemistry. 4 µm thick slides were obtained from 
TMA blocks. Slides were then deparaffinised according to 
standard protocol by xylene, and dehydrated with 95-96% 
ethanol, 70% ethanol and distilled water. All slides were 
stained simultaneously using a computer-controlled autostainer 
(Dako TechMate 500 cytomation) and Dako EnVision-Sytem 
(Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) 
and pretreated with 3% Hydrogen Peroxide prior to antibody 
incubation. MLH1 [M1, ready-to-use (RTU), Ventana Medical 
Systems, Inc.; Roche Diagnostics, Basel, Switzerland], MSH6 
(44, RTU; Ventana Medical Systems, Inc.; Roche Diagnostics), 
PMS2 (EPR3947, RTU; Ventana Medical Systems, Inc.; Roche 
Diagnostics), MSH2 (G219-1129, RTU; Ventana Medical 
Systems, Inc.; Roche Diagnostics), MGMT (MT-23.2; Thermo 
Fisher Scientific, Inc., Waltham, MA, USA; 1:20) and CDX2 
(EPR2764Y; Thermo Fisher Scientific, Inc.; 1:200) antibodies 
were used. Secondary antibody binding (all Dako, 1:200) was 
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visualised using a streptavidin ABC-kit (Dako), followed 
by 3,3'-diaminobenzidine (Vector, Peterborough, UK). For 
ERCC1 (8F1, Neomarkers; dilution: 1:100) and β-catenin (14, 
RTU; Ventana Medical Systems, Inc.; Roche Diagnostics) 
slides were stained by a computer-controlled autostainer 
(Ventana BenchMark Ultra; Ventana Medical Systems, Inc.; 
Roche Diagnostics). Polyclonal rabbit anti-APC antibody 
(DP2.5 1:200 Fa; Acris Antibodies; OriGene Technologies, 
Inc., Rockville, MD, USA) were used for APC staining. 
Staining was performed using ChemMate Detection kit 
(Dako) according to recommendations of the manufacturer. 
The antibodies were incubated overnight at 4˚C followed by 
avidin-biotin complex peroxidease technique using amino-
ethylcarbazole for visualization and hematoxylin for nuclear 
counterstaining. All slides were covered with Aquatex (Merck 
KGaA, Darmstadt, Germany).
Evaluation of immunohistochemistry. For the semi-quantitative 
assessment of staining intensity, we adjusted a previously 
published scoring system for each protein and fitted to TMA 
dots. For MSI proteins and for MGMT the staining was evaluated 
according to Bethesda guidelines (18): score 1, more than 10% of 
tumor cell nuclei are positive; score 0, less than 10% of tumor 
cell nuclei positive (but: positive internal control, i.e., stromal 
cells and lymphocytes). The immunostained TMA sections were 
evaluated and scored under a light microscope independently 
by two pathologists in a blinded fashion. Discordant cases were 
reviewed and re-evaluated based on a consensus opinion.
Immunostaining for CDX2, ERCC1 and nuclear β-catenin 
was scored in a three-graded scale: score 0, weak staining in 
less than 10% of the tumor cells; score 1, moderate staining 
in up to 75% of the tumor cells; and score 2, strong nuclear 
staining in more than 75% of the tumor cells. For cytoplasmic 
β-catenin staining a two-graded scale was used: score 0, no 
or weak staining in less than 10% of tumor cells and weaker 
staining compared to normal colonic mucosa; score 1, nuclear 
staining in more than 10% of the tumor cells.
Cytoplasmic and nuclear APC staining was separately 
scored. For nuclear APC staining a two-graded scale was used: 
score 0, No or weaker staining in less than 10% of tumor cells 
and weaker staining compared to normal colonic mucosa; 
score 1, nuclear staining in more than 10% of the tumor cells. 
For cytoplasmic APC staining a three-graded scale was used: 
score 0, no cytoplasmic staining or weak staining in less than 
10% of tumor cells; score 1, 10-75% of the tumor cells with 
moderate intensity; and score 2, more than 75% of the tumor 
cells are positive with high staining intensity. Normal colorectal 
mucosa was set as baseline expression level for APC (score 2).
Statistical analysis. The statistical analyses were performed 
with SAS software (SAS Institute, Inc., Cary, NC, USA). 
Spearman-Rho test was used to evaluate the relationship 
between clinical data, CDX2, MLH1, MSH2, MSH6, PMS2, 
MGMT, ERCC1, APC and β-catenin.
Results
CDX2 expression and its correlation with clinical data. We 
could reach valid expression data for CDX2 (Table I) in 83 of 
101 cases. 32 cases (38.55%) show no nuclear expression. 
Positive stainings (61.45%, n=51/83) can be subdivided into 
two groups: Moderate nuclear expression with score 1 (16.87% 
n=14); and strong positivity with score 2 (44.58% %, n=37). 
Representative photomicrographs of CDX2 immunohisto-
chemistry are depicted in Fig. 1.
Concerning clinical parameters like: Age, gender of the 
patients, grading of the tumor and the number of metastases, 
there was no significant correlation to CDX2 expression. 
Regarding the size of the metastasis a strong negative corre-
lation could be detected (P=0.038). In addition to CDX2, 
ERCC1 expression was also strongly correlated with the size 
of the metastases (P=0.027). Bigger metastasis size diameter 
was seen in cases with CDX2 and ERCC1 loss.
Expression distribution of DNA repair proteins and proteins 
involved in Wnt‑signaling. For MGMT 97 valid cases were 
obtained. Loss of MGMT expression was found in 24 cases 
(24.75%). Representative photomicrographs of MGMT immu-
nohistochemistry are depicted in Fig. 2. Nuclear positivity 
was sustained in 73 cases (75.25%). Out of 94 valid cases for 
ERCC1 we found 29.8% of the cases negative (score 0). Positive 
ERCC1 staining could be in 70.2% of the cases detected (30.8% 
score 1 and 39.4% score 2). Representative photomicrographs 
of ERCC1 immunohistochemistry are depicted in Fig. 3. Both 
MGMT and ERCC1 loss is strongly associated with female 
gender (P=0.011, and P=0.047, respectively).
Regarding MMR proteins, the following distribution 
was seen: Loss of expression was detected in 4.2 to 26% of 
the cases (MLH1 4.2%, MSH2 26%, MSH6 24% and PMS2 
9.5%, respectively) as published before (19). Loss of PMS2 is 
associated with loss of MGMT (P=0.014) and loss of MLH1 
and MSH2 were also associated with loss of ERCC1 (P<0.01, 
and P<0.01, respectively). Representative photomicrographs of 
MMR protein immunohistochemistry are depicted in Fig. 4. 
Expression distribution of β-catenin, and APC proteins are 
depicted in Table I.
Statistical correlations between CDX2 and DNA repair 
proteins. We found statistically strong positive correlation 
between CDX2 and all of analysed DNA repair proteins 
(Table II). These results mean that loss of CDX2 expression 
is strongly associated with loss of expression of DNA repair 
proteins (MMR proteins, MGMT and ERCC1).
Statistical correlations between CDX2, APC and β‑catenin. 
We analysed the possible statistical correlation between 
CDX2 and β-catenin, and APC (Table III). Cytoplasmic, but 
not nuclear β-catenin expression is associated with sustained 
nuclear CDX2 expression (P=0.042). In addition, CDX2 is 
positively correlated with nuclear APC expression (P<0.01). 
Cytoplasmic and nuclear β-catenin is associated also positive 
with each other (P<0.01). Representative photomicrographs 
of APC and β-catenin immunohistochemistry are depicted in 
Figs. 5 and 6, respectively.
Discussion
In this study, we have demonstrated significant correlations 
between CDX2, DNA repair proteins and crucial members 
of Wnt signaling. To our knowledge, this is the first report 
TÓTH et al:  CDX2 EXPRESSION IN COLORECTAL LIVER METASTASIS 3589
performed on human tissue of CRC liver metastasis presenting 
statistically significant correlations between expression of 
CDX2 referring to expression of MMR proteins and key 
proteins of base and nuclear excision repair. Furthermore, we 
show, for the first time, significant correlation between CDX2, 
APC and β-catenin in liver metastasis of CRC.
Loss of CDX2 expression is seen in approximately 30% of 
human CRC and is associated with higher tumor grade (1). We 
found loss of CDX2 expression in 38.55% of the cases. Loss 
of CDX2 expression was negatively correlated with tumor 
size, but no correlation with age, gender of the patients, grade 
of the tumor and the number of metastases. Interestingly, 
ERCC1 expression loss was also correlated with tumor size. 
Furthermore, loss of CDX2 is strongly correlated with loss of 
ERCC1. Thus, we can conclude, that loss of CDX2 or ERCC1 
expression is strongly associated with bigger metastatic tumor 
size. Similar results for ERCC1 were found recently in breast 
cancer (20), but the exact mechanisms are still unclear.
We can demonstrate statistically significant correlations 
between CDX2 and DNA repair proteins: Loss of CDX2 
expression is associated with loss of MMR proteins, MGMT, 
and ERCC1. These results are consistent with literature data 
from primary CRC: MMR‑deficient or MSI high CRCs have 
significant losses of CDX2 expression. In addition, loss of CDX2 
is associated with CIMP-high, more aggressive histomorpho-
logical features, and unfavourable survival (21). In a study on 
primary CRC and its lymph node metastasis reduced expression 
of CDX2 were found to be as predictor of MMR‑deficiency in 
CRC. Moreover, loss of CDX2 is a poor prognostic factor, even 
among patients with MMR‑proficient cancers (22).
Mutations in DNA repair genes are rare in sporadic 
cancers with DNA repair deficiency. However, DNA repair 
deficiency occurs in a majority of sporadic cancers caused 
Table I. Distribution of immunostaining results of CDX2, APC and β-catenin.
Protein Score 0 (%) Score 1 (%) Score 2 (%) No. of valid cases (%)
CDX2 32 (38.55) 14 (16.87) 37 (44.58)   83 (100)
Nuclear APC 62 (61.38) 39 (38.62) - 101 (100)
Cytoplasmic APC 13 (12.87) 75 (74.26) 13 (12.87) 101 (100)
Cytoplasmic β-catenin 37 (38.14) 60 (61.86) -   97 (100)
Nuclear β-catenin 60 (61.86) 21 (21.65) 16 (16.49)   97 (100)
CDX2, caudal type homeobox 2; APC, adenomatous polyposis coli.
Figure 1. Representative examples of caudal type homeobox 2 protein 
expression in colorectal liver metastasis. (A) Score 0, negative staining- 
<10% of the nuclei are stained. (B) Score 1, moderate overexpression in <75% 
of the nuclei. (C) Score 2, strong overexpression in almost all tumor cells. 
Magnification, x200.
Figure 2. Representative examples of O6-methylguanine DNA methyltrans-
ferase protein expression in colorectal liver metastasis. (A) Score 0, negative 
staining- <10% of the nuclei are stained. (B) Score 1, >10% percent of the 
nuclei are positive. Note that in negative cases, stromal cells, lymphocytes 
and hepatocytes are still nuclear positive. Magnification, x200.
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by epigenetic alterations that reduce or silence DNA repair 
gene expression. For example, a majority of primary CRCs 
have reduced MGMT expression due to i.e., methylation of 
the MGMT promoter region (an epigenetic alteration) (23). 
MGMT can be epigenetically depressed in many ways. Beside 
hypermethylation, MGMT can be depressed by di-methylation 
of lysine 9 of histone 3 (24) or by over-expression of a 
number of microRNAs including miR-181d, miR-767-3p and 
miR-603 (25).
Methylation of MGMT promoter region plays a significant 
role not only in carcinogenesis but also predictive for therapy 
response. In glioblastoma multiforme, the methylation state 
of the MGMT gene determined whether patients would be 
responsive to temozolomide therapy (26). On a clinical level, 
this translates into a prolonged survival of glioblastoma 
patients with a methylated MGMT promoter. In addition, 
MGMT methylation can be used to predict patient survival in 
clinical prediction models (27).
Loss of MGMT and ERCC1 expression was associated 
with female sex in our study. Similar data were demonstrated 
in primary CRC for MGMT (28) and for ERCC1 in lung 
cancer (29), thus we can conclude that this phenomenon stay 
maintained in liver metastasis. For ERCC1 our study is the first 
demonstrating statistically significant correlation with female 
gender in CRC. ERCC1 is essential for a functional NER 
system and ERCC1 expression loss may contribute to impaired 
DNA repair capacity thus increasing cancer risk. Reduced 
expression or loss of ERCC1 and MGMT were reported in 
vast majority of CRCs (30,31), and ERCC1 promoter hyper-
methylation in 38% of gliomas, resulting in reduced mRNA 
and protein expression (32). Disturbed ERCC1 protein expres-
sion appears to be an early event in colorectal carcinogenesis: 
reduced or loss of ERCC1 expression was detected in 40% 
of the colonic crypts within early field defects in colorectal 
mucosa (30). Similarly to MGMT, ERCC1 silencing can be 
resulted not only from promoter methylation, but can also be 
evocated by miRNAs repressing its expression (33). Whether 
epigenetic mechanisms reduce ERCC1 and MGMT protein 
expression in liver metastasis of CRC has to be determined 
in methylation studies. In general, the exact role of ERCC1 
should be further elucidated because of its predictive role 
in chemotherapy. Pre-clinical studies have demonstrated its 
important role in determining cisplatin resistance (34).
In summary, loss of CDX2 is associated with each DNA 
repair protein, which we analysed and our results in liver metas-
tasis are in accordance with the literature data originated from 
primary CRC (21,22). Loss of CDX2 has also been found to 
be an independent predictor of the CIMP-high phenotype (22). 
We used MGMT as surrogate marker for CIMP phenotype, 
but it has been noted that studies about MGMT methylation 
and CIMP had inconsistent findings, thus tumors with loss of 
MGMT cannot be clearly classified as CIMP phenotype (35). 
CIMP-high CRCs have been reported to have a different 
clinicopathological features than CIMP-low ones. CIMP-high 
phenotype is associated with older age, cigarette smoking, 
proximal tumor location, female gender, poorly differentiated 
Figure 3. Representative examples of excision repair cross-complementing 1 
protein expression in colorectal liver metastasis. (A) Score 0, no expression 
detectable or faint partial expression in <10% of the tumor cells. (B) Score 1, 
weak to moderate expression of the entire tumor tissue. (C) Score 2, strong 
positivity in the entire tumor tissue. Magnification, x200.
Figure 4. Representative examples of mismatch repair system protein expres-
sion (MutL Homolog 1 staining) in colorectal liver metastasis. (A) Score 0, 
negative staining- <10% of the nuclei are stained. (B) Score 1, >10% percent 
of the nuclei are positive. Note that in negative cases, stromal cells are still 
positive. Magnification, x200.
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Table II. Results of statistical analysis between CDX2, DNA repair proteins and tumor size.
 DNA repair proteins
 ------------------------------------------------------------------------------------------------------------------------
Gene Analysis Tumor size (mm) MLH1 MSH2 MSH6 PMS2 MGMT ERCC1
CDX2 Correlation coefficient ‑0.247a     0.388b  0.334b  0.317b  0.228a  0.236a    0.574b
 Significance (2‑sided) 0.038 <0.001 0.002 0.004 0.040 0.039 <0.001
 Number of valid cases 71 77 82 82 82 77 74
aP<0.05 and bP<0.01. CDX2, caudal type homeobox 2; MLH1, MutL Homolog 1; MSH, MutS protein Homolog; PMS2, postmeiotic segrega-
tion increased 2; MGMT, O6-methylguanine DNA methyltransferase; ERCC1, excision repair cross-complementing 1.
Table III. Results of statistical analysis between CDX2, APC and β-catenin.
  Membranous/cytoplasmic   
Gene Analysis β-catenin Nuclear β-catenin Cytoplasmic APC Nuclear APC
CDX2 Correlation coefficient  0.231a 0.152 0.065    0.415b
 Significance (2‑sided) 0.042 0.183 0.567 <0.001
 Number of valid cases 78 78 79 79
aP<0.05 and bP<0.01. CDX2, caudal type homeobox 2; APC, adenomatous polyposis coli.
Figure 5. Representative examples of APC protein expression in colorectal 
liver metastasis. (A) Cytoplasmic and nuclear expression of APC protein. 
(B) Only cytoplasmic APC positivity in the tumor cells was observed. 
(C) Strong nuclear positivity next to faint cytoplasmic staining. Magnification, 
x400. APC, adenomatous polyposis coli.
Figure 6. Representative examples of β-catenin expression in colorectal 
liver metastasis. (A) Only membranous staining was observed (score 0 for 
cytoplasm and nucleus). (B) Cytoplasmic expression of β-catenin with some 
positive nuclei (score 1 for cytoplasm and nuclei). (C) Diffuse and strong 
cytoplasmic and nuclear staining (score 1 for cytoplasm, and score 2 for 
nuclei). Magnification, x200.
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or mucinous adenocarcinoma, MSI, and BRAF mutation. 
In addition, CIMP-high cancers regardless of microsatellite 
status show a poorer outcome (36). We suggest that MGMT is 
an adequate marker to detect CIMP phenotype.
The Wnt-β-catenin pathway is a crucial signalling pathway 
in control of embryonic development and tissue homeostasis. 
Its deregulation is observed in many cancers (i.e., CRC, 
non-hepatitis-related hepatocellular cancers, cholangiocarci-
noma, desmoid tumor, breast cancer, osteosarcoma etc) (37). 
The pathway is over-activated in almost all colon cancer 
because of mutations of APC tumor suppressor gene, which 
actually represent the initiating event in colorectal carcinogen-
esis (38). Nevertheless, the actual mechanisms, which regulate 
β-catenin still remain highly controversial. Furthermore, 
the exact role of APC in particular is unclear, and the 
consequences of the mutations found in cancer cells are still 
poorly defined (38). Subcellular localisation of APC protein 
is differentially regulated in normal tissues and cell lines: in 
normal human colorectal epithelium, APC is located in the 
nuclei at basal segment of the crypts; in HT29 colon cancer 
cells, truncated APC translocated to the nucleus during early 
apoptosis (39), and cellular APC accumulates in the nucleus 
of sub‑confluent cells but is partly excluded in super‑confluent 
cells (14). Although there is consensus in many areas in the 
field of nuclear APC localization and function, there have also 
been some conflicting results with no apparent resolution. 
Moreover, the specificity of several APC antibodies has been 
investigated, with no clear consensus about the ‘best’ antibody 
to detect APC protein (40). The nuclear transport of APC in 
tumor cells occurs independently of β-catenin translocation to 
the nucleus or plasma membrane (41).
Nuclear accumulation of β-catenin is also observed in 
cancers resulting from mutations in the β-catenin, APC 
or Axin genes (15,42). The APC tumor suppressor binds to 
β-catenin and the scaffold protein Axin to form a complex 
promoting GSK-3β phosphorylation of β-catenin. However, 
overexpression of APC (1-1309), the most frequently occurring 
APC cancer mutant, translocates β-catenin from the nucleus to 
the cytoplasm. This mutant therefore has the ability to bind and 
regulate localization but lacks the Axin binding sites required 
for β-catenin degradation. Therefore, it seems more likely that 
it is the inability of APC to promote β-catenin degradation, 
rather than a lack of export function, that causes the nuclear 
accumulation of β-catenin in APC-mutant tumor cells (14).
Little is known about the connections between CDX2 and 
Wnt signaling pathway. In a study on Caco-2 cells lower CDX2 
expression is associated with endogenous downregulation 
of APC expression, but did not affect GSK3β expression (4). 
Our analysis led to similar results: Reduced expression or loss 
of CDX2 is associated with reduced nuclear APC expression 
(P<0.01). In our study, the cytoplasmic APC expression was not 
associated with CDX2 expression. We assume that although 
CDX2 induce APC expression, which is already proven (4), 
the truncated APC protein cannot be shifted to cytoplasm, but 
we could detect this truncated protein with our antibody. In 
conclusion, truncated APC can be detected with immunohisto-
chemistry and has certainly not lost its full function and can still 
participate in β‑catenin regulation. Thus, APC can still fulfil an 
unexpectedly large spectrum of APC function (38). Furthermore, 
we found statistically significant correlation between CDX2 
and cytoplasmic β-catenin. We think this correlation can be 
explained through the Mucdhl, a common interaction partner 
for β-catenin and CDX2. It has been shown that β-catenin 
interacts with a protocadherin Mucdhl, which is regulated by 
CDX2 in mice. Membrane-bound β-catenin is a consequence of 
interactions to membranous-expressed Mucdhl. Thus, Mucdhl 
can inhibit β-catenin translocation to the nucleus (4).
CDX2 is indeed expressed in all stages of CRC, little is 
known about its expression manner in association with other 
established prognostic or predictive proteins. In this report, 
we have directly demonstrated that CDX2 gene expression 
is strongly associated with DNA repair proteins and crucial 
members of Wnt signaling. Our results further strengthen the 
role of CDX2 in DNA repair and in regulation of APC and 
β-catenin expression. In fact, our analysis is restricted only 
for metastasis, our results strongly suggest potential (func-
tional) interactions between the investigated proteins. To our 
knowledge, this is the first study to investigate CDX2 in this 
context on human liver metastasis of CRC. Although, CDX2 is 
a useful marker in routine diagnostics for CRC, its exact role 
in liver metastasis remains to be further elucidated. In further 
studies should be investigated if primary CRC differs from 
liver metastasis regarding CDX2 expression.
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